NASDAQ:IDYA

IDEAYA Biosciences - IDYA Stock Forecast, Price & News

$17.88

+0.69 (+4.01%)

(As of 11/30/2022 03:59 PM ET)

Add

Compare

Today's Range: $17.17
▼
$18.05
50-Day Range: $12.01
▼
$18.17
52-Week Range: $8.14
▼
$24.50

Volume: 35,425 shs
Average Volume: 497,132 shs
Market Capitalization: $860.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.14

IDEAYA Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 60.8% Upside
$28.14 Price Target
Short Interest: Bearish
10.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: 0.62
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.49) to ($2.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

615th out of 1,043 stocks

Pharmaceutical Preparations Industry

302nd out of 510 stocks

3.4

Analyst's Opinion

Consensus Rating
IDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.14, IDEAYA Biosciences has a forecasted upside of 60.8% from its current price of $17.50.
Amount of Analyst Coverage
IDEAYA Biosciences has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.04% of the outstanding shares of IDEAYA Biosciences have been sold short.
Short Interest Ratio / Days to Cover
IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in IDEAYA Biosciences has recently increased by 0.84%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
IDEAYA Biosciences does not currently pay a dividend.
Dividend Growth
IDEAYA Biosciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEAYA Biosciences has received a 75.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEAYA Biosciences is -0.77.

2.6

News and Social Media Coverage

News Sentiment
IDEAYA Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 1 article on an average week.
Search Interest
12 people have searched for IDYA on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of IDEAYA Biosciences is held by insiders.
Percentage Held by Institutions
93.25% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($1.49) to ($2.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEAYA Biosciences is -12.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEAYA Biosciences is -12.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IDEAYA Biosciences has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

November 30, 2022 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $28.14 Average Price Target from Brokerages

November 29, 2022 | finance.yahoo.com

IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022

November 28, 2022 | markets.businessinsider.com

IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

November 21, 2022 | americanbankingnews.com

Robert W. Baird Raises IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $24.00

November 16, 2022 | finance.yahoo.com

Wall Street Analysts Think IDEAYA Biosciences, Inc. (IDYA) Could Surge 32%: Read This Before Placing a Bet

November 10, 2022 | finance.yahoo.com

IDEAYA Biosciences Third Quarter 2022 Earnings: Beats Expectations

November 8, 2022 | finance.yahoo.com

IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates

November 8, 2022 | finance.yahoo.com

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

November 1, 2022 | finance.yahoo.com

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences

October 18, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

October 18, 2022 | finance.yahoo.com

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

October 8, 2022 | reuters.com

IDEAYA Biosciences Inc

October 6, 2022 | seekingalpha.com

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

September 21, 2022 | finance.yahoo.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has caught the attention of institutional investors who hold a sizeable 50% stake

September 15, 2022 | nasdaq.com

IDEAYA Biosciences Drops 10% After Pricing Public Offering Of Shares

September 15, 2022 | marketwatch.com

IDEAYA Biosciences Shares Fall Premarket After Public Offering >IDYA

September 15, 2022 | markets.businessinsider.com

IDEAYA Biosciences Prices Underwritten Public Offering Of 7.62 Mln Shares At $10.50/shr

September 13, 2022 | markets.businessinsider.com

Where IDEAYA Biosciences Stands With Analysts

September 12, 2022 | marketwatch.com

IDEAYA Biosciences Shares Surge on Positive Study Data >IDYA

September 12, 2022 | nasdaq.com

IDEAYA Biosciences Rallies 14% On Positive Study Results From Its Uveal Melanoma Drug Candidate

September 12, 2022 | seekingalpha.com

Ideaya says uveal melanoma candidate shrank tumor in 89% of patients

September 11, 2022 | finance.yahoo.com

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

September 6, 2022 | msn.com

IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia

August 30, 2022 | finance.yahoo.com

IDEAYA Biosciences to Participate in Investor Conferences in September 2022

August 29, 2022 | nasdaq.com

IDEAYA Reports Preclinical Development Milestone In Ongoing IND-enabling Studies With GSK

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Company Calendar

Last Earnings: 11/15/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IDYA
CUSIP: N/A
CIK: 1676725
Web: www.ideayabio.com
Phone: (650) 443-6209
Fax: N/A
Employees: 81
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.14
High Stock Price Forecast: $46.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +57.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,760,000.00
Net Margins: -105.60%
Pretax Margin: -105.60%
Return on Equity: -17.15%
Return on Assets: -14.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.02
Quick Ratio: 12.02

Sales & Book Value

Annual Sales: $27.94 million
Price / Sales: 30.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.66 per share
Price / Book: 2.33

Miscellaneous

Outstanding Shares: 48,110,000
Free Float: 45,707,000
Market Cap: $860.21 million
Optionable: Not Optionable
Beta: 0.99

Key Executives

Mr. Yujiro S. Hata (Age 48)
Co-Founder, CEO, Pres & Director
Comp: $798.72k

Mr. Paul A. Stone (Age 58)
Sr. VP, CFO & Principal Accounting Officer
Comp: $551.44k

Dr. Michael A. White Ph.D. (Age 57)
Sr. VP & Chief Scientific Officer
Comp: $261k

Dr. Jeffrey Hager Ph.D. (Age 58)
Co-Founder & Member of the Scientific Advisory Board

Mr. Andres Ruiz Briseno CPA (Age 36)
VP and Head of Bus. Operations & IR

Mr. Jason S. Throne J.D. (Age 50)
Esq., Sr. VP, Gen. Counsel & Company Sec.

Dr. Paul A. Barsanti Ph.D.
Sr. VP & Head of Drug Discovery

Dr. Matthew Maurer M.D.
VP and Head of Medical Affairs & Clinical Oncology

Mr. Mick O'Quigley
Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDYA Stock - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.
What is IDEAYA Biosciences' stock price forecast for 2023?: 7 Wall Street analysts have issued 1-year price targets for IDEAYA Biosciences' stock. Their IDYA share price forecasts range from $13.00 to $46.00. On average, they expect the company's stock price to reach $28.14 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.
How have IDYA shares performed in 2022?: IDEAYA Biosciences' stock was trading at $23.64 at the start of the year. Since then, IDYA stock has decreased by 24.1% and is now trading at $17.95.
View the best growth stocks for 2022 here.
When is IDEAYA Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our IDYA earnings forecast.
How were IDEAYA Biosciences' earnings last quarter?: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The business earned $8.98 million during the quarter, compared to the consensus estimate of $9.49 million. IDEAYA Biosciences had a negative net margin of 105.60% and a negative trailing twelve-month return on equity of 17.15%.
What other stocks do shareholders of IDEAYA Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?: (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.
What is IDEAYA Biosciences' stock symbol?: IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."
Who are IDEAYA Biosciences' major shareholders?: IDEAYA Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Logos Global Management LP (8.59%), BVF Inc. IL (6.85%), Federated Hermes Inc. (5.95%), BlackRock Inc. (5.56%), Vanguard Group Inc. (4.00%) and State Street Corp (3.95%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends.
How do I buy shares of IDEAYA Biosciences?: Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IDEAYA Biosciences' stock price today?: One share of IDYA stock can currently be purchased for approximately $17.95.
How much money does IDEAYA Biosciences make?: IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $863.57 million and generates $27.94 million in revenue each year. The company earns $-49,760,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.
How can I contact IDEAYA Biosciences?: IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.

This page (NASDAQ:IDYA) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IDEAYA Biosciences - IDYA Stock Forecast, Price & News

IDEAYA Biosciences MarketRank™ Forecast

Overall MarketRank™